| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-05-10 | Immunovia (Sweden) Knight Cancer Institute at Oregon Health & Science University (OHSU) (USA - OR) | IMMray™ PanCan-d | pancreatic cancer | collaboration |
Cancer - Oncology - Diagnostic | Collaboration agreement |
| 2015-05-08 | National Cancer Center of Japan (Japan) Takeda Pharmaceutical (Japan) | SCRUM-Japan | R&D collaboration |
Cancer - Oncology | R&D agreement | |
| 2015-05-07 | Paion (Germany) | nomination |
Nomination | |||
| 2015-05-07 | Oxford Biomedica (UK) | nomination |
Nomination | |||
| 2015-05-07 | Asterias Biotherapeutics (USA - CA) | nomination |
Regenerative Medicine | Nomination | ||
| 2015-05-07 | Kiadis Pharma (The Netherlands) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-05-07 | Lonza (Switzerland) Nikon (Japan) | cell and gene therapy manufacturing services | production manufacturing |
Technology - Services | Production agreement | |
| 2015-05-06 | ImmuPharma (UK) | nomination |
Autoimmune diseases | Nomination | ||
| 2015-05-06 | Juno Therapeutics (USA - WA) Fate Therapeutics (USA - CA) | small molecules modulating genetically-engineered T cell product candidates | licensing collaboration |
Cancer - Oncology | Licensing agreement | |
| 2015-05-06 | Eli Lilly (USA - IN) | Lilly Cambridge Innovation Center | construction of new premises |
Construction of new premises | ||
| 2015-05-06 | Pfizer (USA - NY) | nomination |
Nomination | |||
| 2015-05-06 | Lundbeck (Denmark) | nomination |
Nomination | |||
| 2015-05-05 | CMC Biologics (Denmark - USA) Emergent BioSolutions (USA - MD) | Ixinity® (coagulation factor IX) | hemophilia B | manufacturing production |
Rare diseases - Genetic diseases - Hematological diseases | Production agreement |
| 2015-05-05 | Celyad previously known as Cardio3 Biosciences (Belgium) | name change |
Cardiovascular diseases - Regenerative medicine | Establishment of a new subsidiary in the EU | ||
| 2015-05-05 | Novasep (France) | nomination |
Technology - Services | Nomination | ||
| 2015-05-05 | Selvita (Poland) | establishment of a new subsidiary in the EU |
Technology - Services | Establishment of a new subsidiary in the EU | ||
| 2015-05-04 | Clearside Biomedical (USA - GA) Santen (Japan) | CLS1001 (triamcinolone acetonide), drugs to treat diseases afflicting the retina and choroid | glaucoma, posterior ocular diseases | R&D |
Ophtalmological diseases | R&D agreement |
| 2015-05-04 | Macrocure (Israel) | nomination |
Nomination | |||
| 2015-05-04 | Immune Pharmaceuticals (Israel) STC Biologics (USA - MA) | NanomAbs | collaboration development |
Cancer - Oncology | Collaboration agreement | |
| 2015-05-04 | Shire (UK - USA) Foundation Fighting Blindness (USA - MD) | novel treatment for autosomal dominant retinitis pigmentosa (adRP) | retinitis pigmentosa | collaboration R&D |
Rare diseases - Genetic diseases - Ophtalmological diseases | R&D agreement |
